Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but sever...
Saved in:
Main Authors: | Wu Helena T., Hsu Vanessa, Win Shwe, Xing Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2025-01-01
|
Series: | Visualized Cancer Medicine |
Subjects: | |
Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20240019/vcm20240019.html |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01) -
Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01) -
Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01) -
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
by: Konstantinos Lallas, et al.
Published: (2025-01-01) -
Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Population
by: Wang RH, et al.
Published: (2025-02-01)